Plasma p-tau217 as a Clinical Trial Endpoint for Alzheimer Disease
(2026)Objective
To evaluate plasma p-tau217 as a biomarker endpoint for AD clinical trials
Study Summary
• Plasma p-tau217 strongly correlates with amyloid PET and CSF biomarkers, tracks treatment response, and could reduce trial sample sizes by up to 50%.
Intervention
Plasma p-tau217 as trial endpoint (biomarker validation study)
Inclusion Criteria
Participants from multiple AD trials and observational cohorts, cognitively unimpaired through AD dementia
Study Design
Arms: Array
Patients per Arm: Multi-cohort validation
Outcome
Strong correlation with amyloid PET changes (P<0.001). Up to 50% sample size reduction vs cognitive endpoints. Treatment effects detectable at 6 months vs 12–18 months for cognition.
Bottom Line
Plasma p-tau217 strongly correlates with amyloid PET and CSF biomarkers, tracks treatment response, and could reduce trial sample sizes by up to 50%.
Major Points
- Multi-cohort validation showing plasma p-tau217 changes correlate strongly with amyloid PET changes under anti-amyloid therapy (P<0.001).
- Sample size simulations show up to 50% fewer participants needed using p-tau217 vs cognitive endpoints.
- Treatment effects detectable at 6 months with p-tau217 vs 12–18 months for cognitive endpoints.
- Could dramatically reduce cost and duration of AD clinical trials.
- Performance maintained across disease stages from preclinical to AD dementia.
Study Design
- Study Type
- Biomarker validation study
- Randomization
- No
- Blinding
- N/A
- Follow-up
- Variable across cohorts
Primary Outcome
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - | - | - | <0.001 |
Limitations & Criticisms
- Biomarker endpoint may not directly reflect clinical benefit — regulatory acceptance uncertain
- Validation primarily in anti-amyloid trial data — unclear if applies to tau-targeted or other therapies
- Blood-based biomarker variability (diurnal, renal function, BMI) could affect reliability
- Surrogate endpoints in AD have been controversial — amyloid removal did not always translate to clinical improvement
Citation
Neurology. 2026.